Evidence map›Paper›PMID 30476186›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2020

Implementation of a Pragmatic Biomarker-Driven Algorithm to Guide Antibiotic Use in the Pediatric Intensive Care Unit: the Optimizing Antibiotic Strategies in Sepsis (OASIS) II Study.

Kevin J Downes, Julie C Fitzgerald, Emily Schriver, Craig L K Boge, Michael E Russo, Scott L Weiss, Fran Balamuth, Sherri E Kubis, Pam Tolomeo, Warren B Bilker and 4 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Role of biomarkers in pediatric sepsis: What evidence says?World journal of clinical pediatrics · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Procalcitonin in Pediatric Sepsis: What Is It Good for?Journal of the Pediatric Infectious Diseases Society · 2021
    Article
  8. Article
  9. Article
  10. Challenges of Antibiotic Stewardship in the Pediatric and Neonatal Intensive Care Units.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Article
  11. Real-World Application of a Procalcitonin Monitoring Protocol in a Pediatric Intensive Care Unit.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kevin J DownesDivision of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Julie C FitzgeraldDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Emily SchriverCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Craig L K BogeCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Michael E RussoDivision of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Scott L WeissDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Fran BalamuthCenter for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Sherri E KubisDepartment of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Pam TolomeoCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Warren B BilkerCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Jennifer H HanCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Ebbing LautenbachCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Susan E CoffinDivision of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Jeffrey S GerberDivision of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

Pediatric septic acute kidney injury: personalizing antibiotic dosing through understanding acute kidney injury risk factors and biomarker profilesK23DK119463 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI FITZGERALD, JULIE C. HOLLOWS · 2020 to 2024
$810k
Optimizing Vancomycin Therapy in ChildrenK23HD091365 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI DOWNES, KEVIN JAMES · 2018 to 2022
$747k
Mitochondrial Dysfunction in Pediatric SepsisK23GM110496 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI WEISS, SCOTT L · 2015 to 2018
$723k
RNA Expression Profiling in Pediatric Patients with Suspected SepsisK23HD082368 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI BALAMUTH, FRANCES B · 2015 to 2017
$413k
NCEZID CDC HHS U54 CK000485NICHD NIH HHS K23 HD082368NICHD NIH HHS K23 HD091365NIDDK NIH HHS K23 DK119463NIGMS NIH HHS K23 GM110496
6 · The paper itself

Abstract

backgroundBiomarkers can facilitate safe antibiotic discontinuation in critically ill patients without bacterial infection.

methodsWe tested the ability of a biomarker-based algorithm to reduce excess antibiotic administration in patients with systemic inflammatory response syndrome (SIRS) without bacterial infections (uninfected) in our pediatric intensive care unit (PICU). The algorithm suggested that PICU clinicians stop antibiotics if (1) C-reactive protein <4 mg/dL and procalcitonin <1 ng/mL at SIRS onset and (2) no evidence of bacterial infection by exam/testing by 48 hours. We evaluated excess broad-spectrum antibiotic use, defined as administration on days 3-9 after SIRS onset in uninfected children. Incidence rate ratios (IRRs) compared unadjusted excess length of therapy (LOT) in the 34 months before (Period 1) and 12 months after (Period 2) implementation of this algorithm, stratified by biomarker values. Segmented linear regression evaluated excess LOT among all uninfected episodes over time and between the periods.

resultsWe identified 457 eligible SIRS episodes without bacterial infection, 333 in Period 1 and 124 in Period 2. When both biomarkers were below the algorithm's cut-points (n = 48 Period 1, n = 31 Period 2), unadjusted excess LOT was lower in Period 2 (IRR, 0.53; 95% confidence interval, 0.30-0.93). Among all 457 uninfected episodes, there were no significant differences in LOT (coefficient 0.9, P = .99) between the periods on segmented regression.

conclusionsImplementation of a biomarker-based algorithm did not decrease overall antibiotic exposure among all uninfected patients in our PICU, although exposures were reduced in the subset of SIRS episodes where biomarkers were low.

Indexed as

AlgorithmsAntimicrobial StewardshipAdolescentAnti-Bacterial AgentsBacterial InfectionsBiomarkersChildChild, PreschoolC-Reactive ProteinDiagnosis, DifferentialFemaleHumansInfantIntensive Care Units, PediatricLinear ModelsMaleAnti-Bacterial AgentsBiomarkersC-Reactive ProteinProcalcitoninantimicrobial stewardshipbiomarkerscritical carepediatrics

Identifiers

PMID30476186
PMCPMC7317158
OpenAlexW2900932496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.